Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non–Small Cell Lung CancerMark N. Adams, Kenneth J. O’Byrne|Journal of Thoracic Oncology|2017Cited by 84
The Role of Palmitoylation in Signalling, Cellular Trafficking and Plasma Membrane Localization of Protease-Activated Receptor-2Mark N. Adams, John D. Hooper|PLoS ONE|2011Cited by 52
Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapyKatrina Kildey, Mark N. Adams|Communications Biology|2021Cited by 26
hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen‐induced transcriptional response in prostate cancerMark N. Adams, Derek J. Richard|The Prostate|2023Cited by 13
Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung CancerKatherine B. Sahin, Mark N. Adams|Cancers|2021Cited by 11